



Global Action. Local Change.

KDIGO Controversies Conference on Optimal Anemia Management in CKD

**December 13-15, 2019
Barcelona, Spain**

Kidney Disease: Improving Global Outcomes (KDIGO) is an international organization whose mission is to improve the care and outcomes of kidney disease patients worldwide by promoting coordination, collaboration, and integration of initiatives to develop and implement clinical practice guidelines. Periodically, KDIGO hosts conferences on topics of importance to patients with kidney disease. These conferences are designed to review the state of the art on a focused subject and ask what needs to be done in this area to improve patient care and outcomes. Sometimes the recommendations from these conferences lead to KDIGO guideline updating efforts and other times they highlight areas for which additional research is needed.

BACKGROUND

Anemia and disordered iron homeostasis are prevalent in patients with chronic kidney disease (CKD) and associated with significant adverse consequences.¹⁻¹⁵ In 2012, KDIGO issued an anemia guideline, providing recommendations on the diagnosis, evaluation, and treatment of anemia in CKD, including the use of iron agents, erythropoiesis stimulating agents (ESAs), and red-cell transfusions.¹⁶ As noted in the 2012 guideline, the recognition of adverse clinical outcomes associated with ESAs when dosed to normalize hemoglobin,¹⁷⁻²⁰ and several regulatory and reimbursement changes have shifted practice patterns in many countries toward increasing use of iron supplementation.²¹⁻²⁵ In 2014, KDIGO convened a Controversies Conference on iron therapies, focused primarily on potential safety issues, including iron overload; inflammation and oxidative stress; risk of infections; and hypersensitivity reactions.²⁶ At that time, the data were judged insufficient to consider new recommendations, but future research priorities were identified, including an urgent need for more randomized controlled trials.²⁶



Since the 2012 KDIGO anemia guideline and 2014 Controversies Conference, new basic research data, epidemiological studies and randomized trials have emerged that warrant a re-examination of a number of guideline recommendations. These include new molecular insights into the regulation of iron homeostasis by the hepcidin-ferroportin axis and hypoxia inducible factors (HIFs); the pathophysiology of dysregulated iron homeostasis and anemia in CKD; the relationship between iron status, anemia, iron therapy, ESAs and associated co-morbidities/outcomes in CKD patients (e.g., infection, cardiovascular outcomes, mortality); and new data regarding links between iron and anemia and other disorders, including CKD-mineral and bone disorder (CKD-MBD).²⁷⁻³⁹ Most notably, new randomized controlled trial data surrounding the use of existing therapies and new therapeutic agents, including iron-based phosphate binders, iron-containing dialysate, novel iron formulations, long-acting erythropoiesis-stimulating agents (ESAs), ESA biosimilars, and hypoxia-inducible factor (HIF)-stabilizers⁴⁰⁻⁴⁹ provide, in our opinion, sufficient justification to revisit specific guideline recommendations by the future Work Group panel.

Therefore, KDIGO will convene a pair of Controversies Conferences to review the latest evidence, explore new and ongoing controversies, propose a research agenda, and assess change implications for the current KDIGO anemia guideline. It is understood that studies of the effects of HIF-stabilizers on CKD patient outcomes are still in progress. Consequently, the first conference that will be held in December 2019 will focus largely on iron, including the contribution of iron pathophysiology to the anemia of CKD and adverse patient outcomes, diagnostic issues, treatment targets, iron therapeutic agents, and the impact of other current and emerging anemia therapies on hemoglobin targets, iron parameters, and iron supplementation needs. It is anticipated that the second conference will be convened in 2020 to discuss erythropoiesis-stimulating agents, including epoetins and HIF-stabilizers, once additional longer-term outcomes trial data have accrued.

CONFERENCE OVERVIEW

The objective of the December 2019 KDIGO conference is to gather a global panel of multidisciplinary clinical and scientific expertise (i.e., nephrology, cardiology, pediatrics,



pharmacology, hematology etc.) to identify key issues relevant to the optimal management of anemia in CKD, with particular focus on iron. The goal of this KDIGO conference is to determine best practice and areas of uncertainties in the treatment of anemia, review key relevant literature published since the 2012 KDIGO Anemia Guideline, address ongoing controversial issues, identify new topics or issues to be revisited for the next iteration of the KDIGO guideline, and outline research needed to improve anemia management in CKD.

Drs. Tilman B. Drüeke (INSERM U-1018, Hôpital Paul Brousse, Villejuif, France) and Jodie L. Babitt (Massachusetts General Hospital, Boston, MA, USA) will co-chair this conference. The format of the conference will involve topical plenary session presentations followed by focused discussion groups that will report back to the full group for consensus building. Invited participants and speakers will include worldwide leading experts who will address key clinical issues as outlined in the **Appendix: Scope of Coverage**. The conference output will include publication of a summary report that will help guide KDIGO and others on therapeutic management and future research in anemia and CKD.

References

1. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. *PLoS One* 2014; **9**: e84943.
2. St Peter WL, Guo H, Kabadi S, *et al*. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. *BMC Nephrol* 2018; **19**: 67.
3. Ryu SR, Park SK, Jung JY, *et al*. The Prevalence and Management of Anemia in Chronic Kidney Disease Patients: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). *J Korean Med Sci* 2017; **32**: 249-256.

4. Akizawa T, Okumura H, Alexandre AF, *et al.* Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review. *Ther Apher Dial* 2018; **22**: 444-456.
5. Li Y, Shi H, Wang WM, *et al.* Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter, cross-sectional study. *Medicine (Baltimore)* 2016; **95**: e3872.
6. Iyawe IO, Adejumo OA, Iyawe LI, *et al.* Assessment of iron status in predialysis chronic kidney disease patients in a Nigerian Tertiary Hospital. *Saudi J Kidney Dis Transpl* 2018; **29**: 1431-1440.
7. Hayashi T, Tanaka Y, Iwasaki M, *et al.* Association of Circulatory Iron Deficiency With an Enlarged Heart in Patients With End-Stage Kidney Disease. *J Ren Nutr* 2019; **29**: 39-47.
8. Eisenga MF, Nolte IM, van der Meer P, *et al.* Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease. *BMC Nephrol* 2018; **19**: 225.
9. Sato Y, Fujimoto S, Konta T, *et al.* Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease. *Clin Exp Nephrol* 2018; **22**: 388-394.
10. Eriksson D, Goldsmith D, Teitsson S, *et al.* Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. *BMC Nephrol* 2016; **17**: 97.
11. Shaker AM, Mohamed OM, Mohamed MF, *et al.* Impact of correction of anemia in end-stage renal disease patients on cerebral circulation and cognitive functions. *Saudi J Kidney Dis Transpl* 2018; **29**: 1333-1341.
12. Eisenga MF, Minovic I, Berger SP, *et al.* Iron deficiency, anemia, and mortality in renal transplant recipients. *Transpl Int* 2016; **29**: 1176-1183.
13. Majernikova M, Rosenberger J, Prihodova L, *et al.* Posttransplant Anemia as a Prognostic Factor of Mortality in Kidney-Transplant Recipients. *Biomed Res Int* 2017; **2017**: 6987240.

14. Yi SW, Moon SJ, Yi JJ. Low-normal hemoglobin levels and anemia are associated with increased risk of end-stage renal disease in general populations: A prospective cohort study. *PLoS One* 2019; **14**: e0215920.
15. van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. *Nat Rev Nephrol* 2019; doi: 10.1038/s41581-019-0197-5.
16. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney Int Suppl* 2012; 2: 279–335.
17. Pfeffer MA, Burdmann EA, Chen CY, *et al.* A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *N Engl J Med* 2009; **361**: 2019-2032.
18. Drueke TB, Locatelli F, Clyne N, *et al.* Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med* 2006; **355**: 2071-2084.
19. Singh AK, Szczech L, Tang KL, *et al.* Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med* 2006; **355**: 2085-2098.
20. Besarab A, Bolton WK, Browne JK, *et al.* The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *N Engl J Med* 1998; **339**: 584-590.
21. Gardiner R, Roshan D, Brennan A, *et al.* Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience. *Ir J Med Sci* 2019; **188**: 223-230.
22. Evans M, Suttorp MM, Bellocco R, *et al.* Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. *Nephrol Dial Transplant* 2016; **31**: 628-635.
23. Charytan DM, Pai AB, Chan CT, *et al.* Considerations and challenges in defining optimal iron utilization in hemodialysis. *J Am Soc Nephrol* 2015; **26**: 1238-1247.



24. Park H, Liu X, Henry L, *et al.* Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015). *BMC Nephrol* 2018; **19**: 318.
25. Fuller DS, Bieber BA, Pisoni RL, *et al.* International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. *J Am Soc Nephrol* 2016; **27**: 2205-2215.
26. Macdougall IC, Bircher AJ, Eckardt KU, *et al.* Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. *Kidney Int* 2016; **89**: 28-39.
27. Wolf M, Chertow GM, Macdougall IC, *et al.* Randomized trial of intravenous iron-induced hypophosphatemia. *JCI Insight* 2018; **3**.
28. Mehta R, Cai X, Hodakowski A, *et al.* Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study. *Clin J Am Soc Nephrol* 2017; **12**: 1795-1803.
29. Babitt JL, Sitara D. Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease. *Curr Opin Nephrol Hypertens* 2019; **28**: 304-310.
30. Stefanova D, Raychev A, Arezes J, *et al.* Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. *Blood* 2017; **130**: 245-257.
31. Michels KR, Zhang Z, Bettina AM, *et al.* Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia. *JCI Insight* 2017; **2**: e92002.
32. Li X, Cole SR, Kshirsagar AV, *et al.* Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients. *Clin J Am Soc Nephrol* 2019; **14**: 728-737.
33. Hougen I, Collister D, Bourrier M, *et al.* Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis. *Clin J Am Soc Nephrol* 2018; **13**: 457-467.



34. Karaboyas A, Morgenstern H, Pisoni RL, *et al.* Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study. *Nephrol Dial Transplant* 2018; **33**: 2234-2244.
35. Dev S, Babitt JL. Overview of iron metabolism in health and disease. *Hemodial Int* 2017; **21 Suppl 1**: S6-S20.
36. Schwartz AJ, Das NK, Ramakrishnan SK, *et al.* Hepatic hepcidin/intestinal HIF-2alpha axis maintains iron absorption during iron deficiency and overload. *J Clin Invest* 2019; **129**: 336-348.
37. Arezes J, Foy N, McHugh K, *et al.* Erythroferrone inhibits the induction of hepcidin by BMP6. *Blood* 2018; **132**: 1473-1477.
38. Wang CY, Babitt JL. Liver iron sensing and body iron homeostasis. *Blood* 2019; **133**: 18-29.
39. Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. *Nat Rev Nephrol* 2019; doi: 10.1038/s41581-019-0189-5.
40. Meadowcroft AM, Cizman B, Holdstock L, *et al.* Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. *Clin Kidney J* 2019; **12**: 139-148.
41. Holdstock L, Meadowcroft AM, Maier R, *et al.* Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. *J Am Soc Nephrol* 2016; **27**: 1234-1244.
42. Pergola PE, Spinowitz BS, Hartman CS, *et al.* Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. *Kidney Int* 2016; **90**: 1115-1122.
43. Macdougall IC, Akizawa T, Berns JS, *et al.* Effects of Molidustat in the Treatment of Anemia in CKD. *Clin J Am Soc Nephrol* 2019; **14**: 28-39.
44. Chen N, Hao C, Peng X, *et al.* Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. *N Engl J Med* 2019; **381**: 1001-1010.



45. Chen N, Hao C, Liu BC, *et al.* Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. *N Engl J Med* 2019; **381**: 1011-1022.
46. Maccougall IC, White C, Anker SD, *et al.* Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. *N Engl J Med* 2019; **380**: 447-458.
47. Gupta A, Lin V, Guss C, *et al.* Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. *Kidney Int* 2015; **88**: 1187-1194.
48. Fishbane SN, Singh AK, Cournoyer SH, *et al.* Ferric pyrophosphate citrate (Triferic) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. *Nephrol Dial Transplant* 2015; **30**: 2019-2026.
49. Fishbane S, Block GA, Loram L, *et al.* Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. *J Am Soc Nephrol* 2017; **28**: 1851-1858.



APPENDIX: SCOPE OF COVERAGE

Group 1: Iron, anemia, and outcomes in CKD

1. What is the evidence that anemia and/or iron deficiency cause adverse outcomes in CKD patients?
2. What are the known or expected benefits from iron administration (e.g., reduction in mortality and/or morbidity, such as heart failure, cardiovascular disease, hospitalizations, exposure to ESAs, quality of life, fatigue, cognitive function)?
3. What are the known or expected harms from iron administration: (e.g., infection, cardiovascular disease, anaphylaxis, oxidant-mediated tissue injury, diabetes, neurodegenerative disorders, kidney disease progression, cancer)?
4. Are there data to support the known or expected benefits of iron administration, as defined in #2? Are there differential effects by the route of administration or dosing strategy?
5. Are there are data to support the known or expected harms of iron administration, as defined in #3? Are there differential effects by the route of administration or dosing strategy?
6. What is the differential risk of anaphylaxis for the currently available iron formulations? Can we develop a table of reported anaphylactic risk for all available iron formulations to help guide selection?
7. Are there special populations for which intravenous iron supplementation would be beneficial or should be avoided or minimized? What is the evidence to inform the withholding of IV iron supplementation in the context of active infections, hepatitis B or C, dialysis vintage greater than 4 years, use of a catheter rather than a fistula or graft, or other specialized populations?



Global Action. Local Change.

8. How do iron status, anemia, and/or intravenous iron formulations impact CKD-mineral and bone disorder?

9. Do iron status, anemia, and/or iron supplementation affect the host immune response or host microbiome?



Group 2: Pathogenesis and diagnosis of iron deficiency and anemia in CKD

1. What new insights in systemic iron homeostasis have been obtained in the last decade? What is their relevance for new diagnostic and treatment strategies for iron deficiency in the CKD setting? Is this different for inflamed and non-inflamed patients?
2. What is the best definition of iron deficiency and anemia in the CKD setting? Is the definition/diagnosis of iron deficiency still relevant considering the large iron use?
3. What is the prevalence of iron deficiency and anemia in CKD? Is this different for various parts of the world?
4. How can iron deficiency and anemia be diagnosed? What laboratory parameters should be used and what are their limitations? Is there a role for functional tests? Is there a clinical relevance for distinguishing absolute iron deficiency from functional iron deficiency and how should they be defined? Is there a role for novel diagnostic tests?
5. What are the criteria to initiate therapy with ESA/iron? Should we use serum iron parameters (TSAT, ferritin) independent from Hb levels? Should we use clinical or laboratory based criteria or both?
6. Are there differences in prevalence, pathophysiology, diagnosis, treatment initiation criteria for iron deficiency and anemia between patients with CKD (non-dialysis) vs on hemodialysis vs on peritoneal dialysis vs pediatric patients vs kidney transplant recipients?



Group 3: Use of iron agents in CKD anemia management

1. What are the properties, efficacy (e.g., hemoglobin, iron status, functional, and clinical endpoints), and safety profiles (occurrence of hypersensitivity reactions; occurrence of interaction with CKD-MBD parameters [FGF23]) of currently available oral iron agents to be used in anemia of CKD? How do oral iron agents compare with each other? with IV iron agents? How do we define effectiveness? How do we assess equal or unequal effectiveness?
2. What are the properties, efficacy (e.g., hemoglobin, iron status, functional, and clinical endpoints), and safety profiles (occurrence of hypersensitivity reactions; occurrence of interaction with CKD-MBD parameters [FGF23]) of currently available intravenous iron preparations to be used in anemia of CKD? What is the evidence-based data directly comparing efficacy and/or safety among different intravenous iron preparations (e.g., modern versus classic iron preparations and their stability and ligand properties)?
3. What should be the optimal treatment strategy with iron supplementation (e.g., how do we define different dosing regimens/strategies: high dose, low dose, maintenance, bolus, reactive versus proactive)? What are the optimal doses, frequency of administration, dosing strategies? Is there a maximal allowable dose?
4. What should be the optimal treatment targets? Which iron status parameters should be monitored: TSAT, ferritin, other parameters? How frequently should iron parameters be monitored? Does active therapy impact interpretation of iron status parameters? What guidance is there for the termination of iron therapy? Should there be an upper limit of TSAT and/or ferritin, and if so what is it? Is there a hemoglobin level at which iron supplementation should occur regardless of iron indices or at which iron supplementation should not occur? Is there a rationale for iron supplementation irrespective of iron indices?
5. How do we monitor for toxicity? Topics specifically to discuss: Which tests can be used to assess for iron overload/iron toxicity (e.g., MRI, labile iron, oxidative stress parameters)? What is the evidence demonstrating that these tests function as indicators of toxicity? What are their limitations (availability, cost, etc.)?
6. How to use iron supplementation in various patient populations? Should the choice of iron preparation, dosing strategy, treatment targets, or other parameters be modified



Global Action. Local Change.

(and how so) in different patient populations (e.g., patients with CKD [non-dialysis] vs on hemodialysis vs on peritoneal dialysis vs pediatric patients vs kidney transplant recipients; patients with an active infection; patients with liver disease; patients with heart failure; patients with calciphylaxis; other special circumstances)?

Group 4: Impact of ESAs and novel therapeutic agents (e.g., HIFs) in relation to hemoglobin control, iron status, and iron supplementation needs

1. How do ESAs affect iron-related outcomes (i.e., iron parameters, iron supplementation needs)? Is there any impact of ESA dosing strategies (e.g., dose, frequency, rate of titration, use of protocols/artificial intelligence for decision support)?
2. Are there differences among ESA preparations relative to their impact on iron parameters/needs? Are there differences between short- or long-acting ESAs?
3. Is there evidence demonstrating an impact of biosimilars on iron-related outcomes (i.e., iron parameters, iron supplementation needs)? What is the evidence comparing biosimilars with originator ESAs?
4. What are the molecular mechanisms by which HIF stabilizers might impact iron homeostasis (e.g., via EPO production, hepcidin/ferroportin axis, iron transporters, inflammation, EPO-independent bone marrow effects)?
5. What is the evidence from Phase 2/3 clinical trials on the impact of HIF stabilizers compared with placebo or ESA on hemoglobin response, iron status, and iron supplementation needs in CKD patients? What is the therapeutic window of HIF stabilizers for impacting hemoglobin response, iron metabolism? Are there differences among HIF stabilizers, theoretical or demonstrated?
6. What new therapeutic strategies are being developed to treat iron deficiency and anemia in CKD patients (targeting hepcidin/ferroportin axis, activin receptor ligand traps, etc.)?
7. Is there a role for combination therapies/multi-target approach to treat anemia of CKD? Why only a single or two agent therapy? Should we target inflammation? Are there other adjunctive therapies that should be considered?
8. Are there additional biomarkers or diagnostic tests that are relevant to the evaluation and/or management of anemia with new therapeutic agents?
9. What is the evidence regarding cost-effectiveness of novel therapeutic agents for treating anemia of CKD?



Global Action. Local Change.

10. How do / would new therapies impact pediatric patients with kidney disease?
11. What impact do new therapies have on mineral bone metabolism?